Core Insights - The company reported a revenue of RMB 621 million for the six months ending June 30, 2025, representing a year-on-year growth of 51.3% [1] - Shareholder profit reached RMB 47.99 million, marking a turnaround from loss to profit, with earnings per share at RMB 0.12 [1] Business Segments - The preclinical products and services segment, centered on innovative animal model sales, generated revenue of RMB 458 million, a 56.9% increase compared to the same period last year, with a gross margin of approximately 70% [1] - The antibody discovery business achieved revenue of RMB 163 million, a 37.8% increase year-on-year, with a gross margin of around 90% [2] - The company signed approximately 280 agreements for therapeutic antibodies and various clinical asset collaborations, with 80 new contracts signed in the first half of 2025, a 60% increase from the previous year [2] Market Expansion - The company expanded its overseas market presence, achieving revenue of RMB 422 million from international operations, while domestic revenue reached RMB 200 million due to the recovery of the local biopharmaceutical industry [2] - The global network enhances the company's resilience and risk management capabilities, allowing for steady growth through cycles [2] Research and Development - The company maintained high levels of R&D investment, with R&D expenses amounting to RMB 209 million, an increase of RMB 47.74 million year-on-year, resulting in an R&D expense ratio exceeding 30% [3] - The company implemented lean management practices, leading to a continuous decline in management expense ratios [3]
百奥赛图-B(02315)发布中期业绩 股东应占溢利4799.9万元 同比扭亏为盈